Although healthcare companies in the systemic lupus erythematosus treatment market have made significant advances regarding drug development, certain side effects of these drugs are anticipated to negatively influence market growth. For instance, immunosuppressive drugs are estimated to reach a value of ~US$ 1.5 billion by 2027, and continue to dominate the systemic lupus erythematosus treatment market throughout the forecast period. However, enduring disease activity with recurring flare ups and accumulating toxicity due to glucocorticoids (GC) and immunosuppressive (IS) medications are some of the side effects associated with SLE drugs.
Since SLE is a heterogeneous disease of varying severity, healthcare companies in the systemic lupus erythematosus treatment landscape are beginning to understand that, developing 'one size fits all' immunosuppressive drugs increases the burden of symptoms in patients. This is why, healthcare companies in the systemic lupus erythematosus treatment market are adopting the 'treat-to-target' approach to develop drugs that effectively manage and minimize the incidence of disease activity. Healthcare providers are implementing patient-tailored therapeutic strategies with the introduction of improved biologic agents.
With the help of successful randomized controlled trials (RCTs) and approvals from health commissions, healthcare companies in the systemic lupus erythematosus treatment market are capitalizing on improved formulations of biologic agents. Other drugs such as biologics and B-cell modulators are projected to be the second-highest revenue generating source for manufacturers, with a value of ~US$ 785 million by 2027. Due to the increasing availability of belimumab, healthcare companies are gaining credibility, as this antibody is found to be efficacious in minimizing flare ups and disease activity. Thus, belimumab has helped stakeholders in the SLE supply chain to maintain a stable therapeutic armamentarium in the market.
Healthcare companies in the systemic lupus erythematosus treatment market are increasing their focus on novel biologic agents that target B cells, T cells, and cytokines, for improving the quality of life in patients. The market value share of the intravenous mode of delivery is estimated to grow from ~39% currently to ~44% by 2027 in the systemic lupus erythematosus treatment market. This is well justified, as healthcare providers are increasingly diagnosing patients with belimumab through intravenous formulations.
Apart from advancements in drug delivery, healthcare providers in the systemic lupus erythematosus treatment market are offering supportive treatments, since SLE patients are prone to comorbidities. Thus, healthcare companies can supply hospitals and other healthcare providers with vaccinations to prevent common disease problems such as influenza and streptococcus pneumonia. There is also an increasing need for vaccination against the human papilloma virus (HPV) in adult SLE patients.
Maintaining a steady supply chain of calcium and vitamin D supplements can help healthcare companies in the systemic lupus erythematosus treatment market to broaden and increase their bracket for revenue sources. These supplements are highly recommended for patients who are prescribed glucocorticoids, to avoid the risks of GC-induced osteoporosis. Companies should increase research & development to improve bidirectional control of the risk factors associated with cardiovascular diseases (CVD). Doing this will help them understand the disease-related factors associated with the consumption of statins and antihypertensive drugs by CVD patients.
Analysts’ Viewpoint
Analysts of the systemic lupus erythematosus treatment market estimate a promising growth for the market during the forecast period. Healthcare providers should prescribe low-dose aspirin in conjunction with antiphospholipid antibodies (aPL) to reduce cardiovascular events in patients.
However, in many cases, ineffective management of SLE leads to severe drug-induced toxicity and organ deterioration. Thus, healthcare providers are increasing awareness about long-term maintenance therapy with hydroxychloroquine, as this technique has improved the life expectancy of SLE sufferers.
Since belimumab is the only targeted therapy approved by health commissions for the treatment of SLE, healthcare companies should increase their focus on developing new molecular formulations of the antibody.
Systemic Lupus Erythematosus Treatment Market: Key Insights
Systemic Lupus Erythematosus Treatment Market: Drivers
Systemic Lupus Erythematosus Treatment Market: Segment Analysis
Systemic Lupus Erythematosus Treatment Market: Geographic Overview
Systemic Lupus Erythematosus Treatment Market: Major Players
Global Systemic Lupus Erythematosus Treatment Market - Segmentation
TMR’s study on the global systemic lupus erythematosus treatment market includes information divided into four segments: drug, mode of delivery, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global systemic lupus erythematosus treatment market are discussed in detail.
|
Drug |
Antimalarial Drugs Non-steroidal Anti-inflammatory Drugs (NSAIDS) Corticosteroids Immunosuppressive Drugs Others (Biologics, B-cell Modulators, etc.) |
|
Mode of Delivery |
Intravenous Subcutaneous Oral |
|
Distribution Channel |
Hospital Pharmacies Retail Pharmacies Online Sales |
|
Region |
North America Europe Asia Pacific Latin America Middle East & Africa |
Systemic lupus erythematosus treatment market to reach a valuation of ~US$ 3 Bn by 2027
Systemic lupus erythematosus treatment market is projected to grow at a CAGR of ~7% from 2019 to 2027
Numerous pipeline products and recent approvals of drugs to treat systemic lupus erythematosus are expected to drive the systemic lupus erythematosus treatment market
The immunosuppressive drugs segment dominated the global systemic lupus erythematosus treatment market, and the trend is likely to continue during the forecast period
Key players in the global systemic lupus erythematosus treatment market include GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca, Merck & Co., Inc.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
3.1. Global Systemic Lupus Erythematosus Treatment Market Snapshot
4. Market Overview
4.1. Product Overview
4.2. Key Industry Events
4.3. Market Dynamics
4.3.1. Drivers and Restraints Snapshot Analysis
4.3.2. Drivers
4.3.3. Restraints
4.3.4. Opportunities
4.4. Global Systemic Lupus Erythematosus Treatment Market Revenue Projection
4.5. Global Systemic Lupus Erythematosus Treatment Market Outlook
5. Market Outlook
5.1. Key Mergers & Acquisitions
5.2. Pipeline Analysis
5.3. Disease Prevalence & Incidence Rate Globally with Key Countries
6. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Drug
6.1. Introduction
6.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
6.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
6.3.1. Antimalarial Drugs
6.3.1.1. Chloroquine
6.3.1.2. Hydrochloroquine
6.3.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
6.3.2.1. Ibuprofen
6.3.2.2. Naproxen
6.3.2.3. Others
6.3.3. Corticosteroids
6.3.3.1. Prednisone
6.3.3.2. Hydrocortisone
6.3.3.3. Dexamethasone
6.3.3.4. Others
6.3.4. Immunosuppressive Drugs
6.3.4.1. Azathioprine
6.3.4.2. Cyclophosphamide
6.3.4.3. Methotrexate
6.3.4.4. Others
6.3.5. Others (Biologics, B-cell Modulators, etc.)
7. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Mode of Delivery
7.1. Introduction
7.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Mode of Delivery
7.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Mode of Delivery
7.3.1. Intravenous
7.3.2. Subcutaneous
7.3.3. Oral
7.4. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Mode of Delivery
8. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Distribution Channel
8.1. Introduction
8.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
8.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Sales
8.4. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Distribution Channel
9. Global Systemic Lupus Erythematosus Treatment Market Analysis, by Region
9.1. Global Systemic Lupus Erythematosus Treatment Market Scenario, by Country
9.2. Global Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Region
9.3. Global Systemic Lupus Erythematosus Treatment Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America Systemic Lupus Erythematosus Treatment Market Analysis
10.1. Key Findings
10.2. North America Systemic Lupus Erythematosus Treatment Market Overview
10.3. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country
10.4. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Country
10.4.1. U.S.
10.4.2. Canada
10.5. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
10.6. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
10.6.1. Antimalarial Drugs
10.6.1.1. Chloroquine
10.6.1.2. Hydrochloroquine
10.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
10.6.2.1. Ibuprofen
10.6.2.2. Naproxen
10.6.2.3. Others
10.6.3. Corticosteroids
10.6.3.1. Prednisone
10.6.3.2. Hydrocortisone
10.6.3.3. Dexamethasone
10.6.3.4. Others
10.6.4. Immunosuppressive Drugs
10.6.4.1. Azathioprine
10.6.4.2. Cyclophosphamide
10.6.4.3. Methotrexate
10.6.4.4. Others
10.6.5. Others (Biologics, B-cell Modulators, etc.)
10.7. North America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
10.8. North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
10.8.1. Intravenous
10.8.2. Subcutaneous
10.8.3. Oral
10.9. North America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
10.10. North America Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
10.10.1. Hospital Pharmacies
10.10.2. Retail Pharmacies
10.10.3. Online Sales
11. Europe Systemic Lupus Erythematosus Treatment Market Analysis
11.1. Key Findings
11.2. Europe Systemic Lupus Erythematosus Treatment Market Overview
11.3. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.4. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
11.4.1. Germany
11.4.2. U.K.
11.4.3. France
11.4.4. Spain
11.4.5. Italy
11.4.6. Rest of Europe
11.5. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
11.6. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
11.6.1. Antimalarial Drugs
11.6.1.1. Chloroquine
11.6.1.2. Hydrochloroquine
11.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
11.6.2.1. Ibuprofen
11.6.2.2. Naproxen
11.6.2.3. Others
11.6.3. Corticosteroids
11.6.3.1. Prednisone
11.6.3.2. Hydrocortisone
11.6.3.3. Dexamethasone
11.6.3.4. Others
11.6.4. Immunosuppressive Drugs
11.6.4.1. Azathioprine
11.6.4.2. Cyclophosphamide
11.6.4.3. Methotrexate
11.6.4.4. Others
11.6.5. Others (Biologics, B-cell Modulators, etc.)
11.7. Europe Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
11.8. Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
11.8.1. Intravenous
11.8.2. Subcutaneous
11.8.3. Oral
11.9. Europe Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
11.10. Europe Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
11.10.1. Hospital Pharmacies
11.10.2. Retail Pharmacies
11.10.3. Online Sales
12. Asia Pacific Systemic Lupus Erythematosus Treatment Market Analysis
12.1. Key Findings
12.2. Asia Pacific Systemic Lupus Erythematosus Treatment Market Overview
12.3. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.4. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
12.4.1. Japan
12.4.2. China
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
12.6. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
12.6.1. Antimalarial Drugs
12.6.1.1. Chloroquine
12.6.1.2. Hydrochloroquine
12.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
12.6.2.1. Ibuprofen
12.6.2.2. Naproxen
12.6.2.3. Others
12.6.3. Corticosteroids
12.6.3.1. Prednisone
12.6.3.2. Hydrocortisone
12.6.3.3. Dexamethasone
12.6.3.4. Others
12.6.4. Immunosuppressive Drugs
12.6.4.1. Azathioprine
12.6.4.2. Cyclophosphamide
12.6.4.3. Methotrexate
12.6.4.4. Others
12.6.5. Others (Biologics, B-cell Modulators, etc.)
12.7. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
12.8. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
12.8.1. Intravenous
12.8.2. Subcutaneous
12.8.3. Oral
12.9. Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
12.10. Asia Pacific Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Sales
13. Latin America Systemic Lupus Erythematosus Treatment Market Analysis
13.1. Key Findings
13.2. Latin America Systemic Lupus Erythematosus Treatment Market Overview
13.3. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.4. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
13.6. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
13.6.1. Antimalarial Drugs
13.6.1.1. Chloroquine
13.6.1.2. Hydrochloroquine
13.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
13.6.2.1. Ibuprofen
13.6.2.2. Naproxen
13.6.2.3. Others
13.6.3. Corticosteroids
13.6.3.1. Prednisone
13.6.3.2. Hydrocortisone
13.6.3.3. Dexamethasone
13.6.3.4. Others
13.6.4. Immunosuppressive Drugs
13.6.4.1. Azathioprine
13.6.4.2. Cyclophosphamide
13.6.4.3. Methotrexate
13.6.4.4. Others
13.6.5. Others (Biologics, B-cell Modulators, etc.)
13.7. Latin America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
13.8. Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
13.8.1. Intravenous
13.8.2. Subcutaneous
13.8.3. Oral
13.9. Latin America Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
13.10. Latin America Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Sales
14. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Overview
14.3. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.4. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Country/Sub-region
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. Rest of Middle East & Africa
14.5. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Drug
14.6. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Drug
14.6.1. Antimalarial Drugs
14.6.1.1. Chloroquine
14.6.1.2. Hydrochloroquine
14.6.2. Non-steroidal Anti-inflammatory Drugs (NSAIDS)
14.6.2.1. Ibuprofen
14.6.2.2. Naproxen
14.6.2.3. Others
14.6.3. Corticosteroids
14.6.3.1. Prednisone
14.6.3.2. Hydrocortisone
14.6.3.3. Dexamethasone
14.6.3.4. Others
14.6.4. Immunosuppressive Drugs
14.6.4.1. Azathioprine
14.6.4.2. Cyclophosphamide
14.6.4.3. Methotrexate
14.6.4.4. Others
14.6.5. Others (Biologics, B-cell Modulators, etc.)
14.7. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery
14.8. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery
14.8.1. Intravenous
14.8.2. Subcutaneous
14.8.3. Oral
14.9. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share and Attractiveness Analysis, by Distribution Channel
14.10. Middle East & Africa Systemic Lupus Erythematosus Treatment Market Forecast, by Distribution Channel
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Sales
15. Competitive Landscape
15.1. Competition Matrix
15.2. Company Profile
15.2.1. GlaxoSmithKline plc
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Financial Overview
15.2.1.3. Product Portfolio
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. F. Hoffmann-La Roche Ltd.
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Financial Overview
15.2.2.3. Product Portfolio
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Pfizer, Inc.
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Financial Overview
15.2.3.3. Product Portfolio
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. AstraZeneca plc
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Financial Overview
15.2.4.3. Product Portfolio
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Merck & Co., Inc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Financial Overview
15.2.5.3. Product Portfolio
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Bristol-Myers Squibb Company
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Financial Overview
15.2.6.3. Product Portfolio
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Anthera Pharmaceuticals, Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Financial Overview
15.2.7.3. Product Portfolio
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. ImmuPharma PLC
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. SWOT Analysis
15.2.8.4. Strategic Overview
15.2.9. Aurinia Pharmaceuticals, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. SWOT Analysis
15.2.9.4. Strategic Overview
List of Tables
Table 01: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 02: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027
Table 03: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027
Table 04: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027
Table 05: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027
Table 06: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027
Table 07: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 08: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 09: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 10: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 11: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027
Table 12: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027
Table 13: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027
Table 14: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027
Table 15: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027
Table 16: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 17: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 18: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 19: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027
Table 20: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027
Table 21: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027
Table 22: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027
Table 23: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027
Table 24: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 25: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 26: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 27: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027
Table 28: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027
Table 29: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027
Table 30: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027
Table 31: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027
Table 32: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 33: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 34: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 35: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027
Table 36: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027
Table 37: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027
Table 38: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027
Table 39: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027
Table 40: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
Table 41: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 42: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Drug, 2017–2027
Table 43: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Antimalarial Drugs, 2017–2027
Table 44: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027
Table 45: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Corticosteroids, 2017–2027
Table 46: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Immunosuppressive Drugs, 2017–2027
Table 47: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Mode of Delivery, 2017–2027
Table 48: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2027
List of Figures
Figure 01: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) and Distribution (%), by Region, 2018 and 2027
Figure 02: Global Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) and Forecast, 2019–2027
Figure 03: Global Systemic Lupus Erythematosus Treatment Market Value Share (%), by Drug, 2018
Figure 04: Global Systemic Lupus Erythematosus Treatment Market Value Share (%), by Mode of Delivery, 2018
Figure 05: Global Systemic Lupus Erythematosus Treatment Market Value Share (%), by Distribution Channel, 2018
Figure 06: Global Systemic Lupus Erythematosus Treatment Market Value Share (%), by Region, 2018
Figure 07: Global Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027
Figure 08: Global Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027
Figure 09: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Antimalarial Drugs, 2017–2027
Figure 10: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Non-steroidal Anti-inflammatory Drugs (NSAIDS), 2017–2027
Figure 11: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2017–2027
Figure 12: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Immunosuppressive Drugs, 2017–2027
Figure 13: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others (Biologics, B-cell Modulators, etc.), 2017–2027
Figure 14: Global Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027
Figure 15: Global Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027
Figure 16: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intravenous, 2017–2027
Figure 17: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Subcutoneous, 2017–2027
Figure 18: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017–2027
Figure 19: Global Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027
Figure 20: Global Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 21: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027
Figure 22: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027
Figure 23: Global Systemic Lupus Erythematosus Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Sales, 2017–2027
Figure 24: Global Systemic Lupus Erythematosus Treatment Market Value Share, by Region, 2018 and 2027
Figure 25: Global Systemic Lupus Erythematosus Treatment Market Attractiveness, by Region, 2019–2027
Figure 26: North America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 27: North America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Country, 2018 and 2027
Figure 28: North America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Country, 2019–2027
Figure 29: North America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027
Figure 30: North America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027
Figure 31: North America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027
Figure 32: North America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027
Figure 33: North America Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027
Figure 34: North America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 35: Europe Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 36: Europe Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 37: Europe Systemic Lupus Erythematosus Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 38: Europe Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027
Figure 39: Europe Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027
Figure 40: Europe Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027
Figure 41: Europe Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027
Figure 42: Europe Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027
Figure 43: Europe Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 44: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 45: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 46: Asia Pacific Systemic Lupus Erythematosus Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 47: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027
Figure 48: Asia Pacific Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027
Figure 49: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027
Figure 50: Asia Pacific Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027
Figure 51: Asia Pacific Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027
Figure 52: Asia Pacific Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 53: Latin America Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 54: Latin America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 55: Latin America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 56: Latin America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027
Figure 57: Latin America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027
Figure 58: Latin America Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027
Figure 59: Latin America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027
Figure 60: Latin America Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027
Figure 61: Latin America Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Figure 62: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027
Figure 63: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Country/Sub-region, 2018 and 2027
Figure 64: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 65: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Drug, 2018 and 2027
Figure 66: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Attractiveness, by Drug, 2019–2027
Figure 67: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share Analysis, by Mode of Delivery, 2018 and 2027
Figure 68: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Attractiveness, by Mode of Delivery, 2019–2027
Figure 69: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Value Share, by Distribution Channel, 2018 and 2027
Figure 70: Middle East & Africa Systemic Lupus Erythematosus Treatment Market Attractiveness, by Distribution Channel, 2019–2027
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Systemic Lupus Erythematosus Treatment Market
